- Conditions
- Cancer
- Interventions
- Trametinib, Dabrafenib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1585–1608
of 17,150
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Psoriasis
- Interventions
- Apremilast, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
- Conditions
- Breast Cancer
- Interventions
- ISB 1302 250 ng/kg, ISB 1302 325 ng/kg, ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22, ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22, ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22, ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22, ISB 1302 escalating doses,1200 ng/kg D15,22, ISB 1302 at the MTD and/or RP2D dose
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more
- Conditions
- Heart Failure, Congestive
- Interventions
- Seloken ZOK/Toprol-XL, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 41 more
- Conditions
- Frontotemporal Dementia
- Interventions
- AL001
- Drug
- Lead sponsor
- Alector Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania + 1 more
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Interventions
- Azacitidine, Pembrolizumab, Epacadostat, INCB057643, INCB059872
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Chicago, Illinois + 4 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Interventions
- efgartigimod PH20 SC in stage B, placebo in stage B
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Interventions
- Not listed
- Lead sponsor
- Drexel University College of Medicine
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
- Interventions
- Placebo capsules, Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fresno, California + 30 more
- Conditions
- Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
- Interventions
- Dexmedetomidine, Lorazepam 2 MG/ML
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Stage II Prostate Adenocarcinoma AJCC v7
- Interventions
- Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 276
- States / cities
- Mobile, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 230 more
- Conditions
- Continous Flow Left Ventricular Device
- Interventions
- Echo Guided Testing, Hemodynamic-Echo Ramp Testing -
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- San Diego, California • Stanford, California • Chicago, Illinois + 4 more
- Conditions
- HIV Infections, Opioid Use, Trauma, Psychological
- Interventions
- Not listed
- Lead sponsor
- Alexis Roth
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Keratosis, Actinic
- Interventions
- MAL Cream, Vehicle cream
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 52
- States / cities
- Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- HER3-DXd, Osimertinib
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 13
- States / cities
- Santa Monica, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- erlotinib, gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Palm Springs, California • Aurora, Colorado • Chapel Hill, North Carolina + 2 more
- Conditions
- Dermatomyositis
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Louisville, Kentucky • Detroit, Michigan + 2 more
- Conditions
- Elective Cardiac Surgery
- Interventions
- CytoSorb
- Device
- Lead sponsor
- CytoSorbents, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 20
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 16 more
- Conditions
- Opioid-use Disorder, Overdose
- Interventions
- buprenorphine/naloxone
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- ADXS11-001 (Lm-LLO-E7), Placebo Control
- Biological · Drug
- Lead sponsor
- Advaxis, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
- Conditions
- Aggression
- Interventions
- CBI, NUT
- Behavioral · Dietary Supplement
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 11 Years to 12 Years
- Enrollment
- 335 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Myeloid Leukaemia (AML)
- Interventions
- Placebo in combination with Cytarabine Injection, Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamycin for Injection in combination with Cytarabine Injection.
- Drug
- Lead sponsor
- Moleculin Biotech, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Miami, Florida • Augusta, Georgia + 5 more
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Proton Therapy, IMRT
- Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2026
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Philadelphia, Pennsylvania